Immunos Therapeutics raised €9.9M in a Series C round in Sep 2024. The company is based in Schlieren, Switzerland. Investors in the round: BioMed Partners, Double Point Ventures, Gimv and 2 others. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
